Summary
The biochemical modulators PALA, an inhibitor of aspartate transcarbamylase which depletes uridine nucleotide pools, and 6-methylmercaptopurine riboside (MMPR) which inhibits purine metabolism, selectively potentiate the antitumor activity of 5-fluorouracil (5-FU) in preclinical models. Based on a phase I trial of this combination, we performed a phase II trial in patients with advanced pancreatic cancer. PALA 250 mg/m2 was administered i.v. on day 1, followed 24h later by MMPR 150 mg/m2 as a bolus i.v. injection, and 5-FU 2300 mg/m2 by 24h infusion. Treatments were repeated weekly. Seventeen patients, all previously untreated with chemotherapy, were entered, of whom 14 are evaluable for response. Toxicity ≥ grade 2 included nausea (6/17), vomiting (4/17), diarrhea (3/17), stomatitis (5/17), and neurotoxicity (2/17). Among 14 evaluable patients there were no partial responses, and two patients with stable disease. Pretreatment with PALA and MMPR is insufficient to enhance the activity of 5-FU in pancreatic cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brennan MF, Kinsella T, Friedman M: Cancer of the pancreas. In: De Vita VT, Heller S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (3rd ed). Lippincott, Philadelphia, PA, 1989, pp 800–835
Grem JL: Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Lippincott, Philadelphia, PA, 1990, pp 180–224
O'Dwyer PJ: The role of low-dose PALA in biochemical modulation. Pharmac Ther 48:371–380, 1990
Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res 43:2317–2321, 1983
O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF: Phase I trial of 5-fluorouracil modulation by PALA and MMPR: optimization of MMPR dose and schedule through biochemical analysis of sequential tumor biopsy specimens. J Natl Cancer Inst 83:1235–1240, 1991
Hageboutros A, Hudes GR, Brennan J, Green F, Hoffman J, LaCreta FP, Colofiore J, Martin DS, Ozols RF, O'Dwyer PJ: Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. Cancer Chemother Pharmacol (in press), 1994
Miller AB, Hoogstraten B, Staquet Met al.: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Rosvold E, Schilder RJ, Walczak J, DeFino SM, Flynn PJ, Bannerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ: Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 29:305–308, 1992
O'Dwyer PJ, Paul AR, Walczak Jet al.: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497–1503, 1990
Anonymous: Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced colorectal cancer metaanalysis project. J Clin Oncol 12:960–969, 1994
Morrell LM, Bach A, Richman SP, Goodman P, Fleming TR, Macdonald JS: A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study. Cancer 67:363–366, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Redei, I., Green, F., Hoffman, J.P. et al. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Invest New Drugs 12, 319–321 (1994). https://doi.org/10.1007/BF00873047
Issue Date:
DOI: https://doi.org/10.1007/BF00873047